Xilio Therapeutics Inc (NASDAQ:XLO) shares traded 57.32% higher at $1.15 on Wall Street last session.
XLO stock price is now 49.34% away from the 50-day moving average and 29.22% away from the 200-day moving average. The market capitalization of the company currently stands at $59.55M.
With the price target of $7, Chardan Capital Markets recently initiated with Buy rating for Xilio Therapeutics Inc (NASDAQ: XLO). On January 10, 2022, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $36, while ‘Raymond James’ rates the stock as ‘Outperform’
In other news, Frankenfield Christopher James, Chief Financial Officer sold 6,954 shares of the company’s stock on Jan 02 ’25. The stock was sold for $6,841 at an average price of $0.98. Upon completion of the transaction, the Chief Financial Officer now directly owns 12,421 shares in the company, valued at $14284.15. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 02 ’25, SVP, FINANCE AND ACCOUNTING Brennan Kevin M. sold 1,803 shares of the business’s stock. A total of $1,774 was realized by selling the stock at an average price of $0.98. This leaves the insider owning 3,197 shares of the company worth $3676.55. A total of 69.41% of the company’s stock is owned by insiders.
During the past 12 months, Xilio Therapeutics Inc has had a low of $0.62 and a high of $1.70. As of last week, the company has a debt-to-equity ratio of 0.73, a current ratio of 1.96, and a quick ratio of 1.96.
The net profit margin was -585.54% and return on equity was -297.84% for XLO.
